Related Experiment Video
Updated: Mar 14, 2026

10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
19.4K
Improving psychotropic medication use among persons with dementia.
1Department of Psychiatry,University of Michigan,Center for Clinical Management Research,VA Ann Arbor Healthcare System,Ann Arbor,Michigan,USA.
International Psychogeriatrics
|September 24, 2016
Summary
Psychotropic medication use in persons with dementia (PWD) is high, despite limited evidence of benefit and known harms. Careful consideration is needed, as ending all use may lead to less effective alternatives.
Area of Science:
- Gerontology
- Psychopharmacology
- Dementia Care
Background:
- Psychotropic medication use in persons with dementia (PWD) is prevalent in both nursing home and community settings.
- This high utilization persists despite substantial evidence of limited benefit and potential harms in older adults, particularly PWD.
- Existing evidence highlights the risks associated with psychotropic medications in this population.
Purpose of the Study:
- To address the issue of high psychotropic medication use in persons with dementia.
- To advocate for a nuanced approach rather than a complete cessation of psychotropic use.
- To highlight the potential negative consequences of overly restrictive policies on medication management for PWD.
Main Methods:
- Literature review of studies on psychotropic medication use in PWD.
- Analysis of evidence regarding the efficacy and risks of psychotropic medications in older adults.
- Examination of policy implications and alternative treatment strategies.
Main Results:
- Psychotropic medication use in PWD significantly exceeds levels supported by evidence of benefit.
- Concerns exist regarding the potential harms of these medications in PWD.
- Policies restricting all psychotropic use may inadvertently promote the use of less-studied alternatives.
Conclusions:
- The high use of psychotropic medications in persons with dementia requires careful management, not outright elimination.
- Individualized patient needs must be considered to ensure appropriate treatment.
- Overly broad restrictions could lead to the adoption of treatments with even less evidence and potentially greater risks.
Related Concept Videos
Drug Therapy
364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
364
Psychosis: Goals of Pharmacotherapy
649
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
649
Drug Dosing: Geriatric Patients
339
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
339
Psychosis and Antipsychotic Drugs: Overview
1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

